UY32296A - Nuevos compuestos - Google Patents

Nuevos compuestos

Info

Publication number
UY32296A
UY32296A UY0001032296A UY32296A UY32296A UY 32296 A UY32296 A UY 32296A UY 0001032296 A UY0001032296 A UY 0001032296A UY 32296 A UY32296 A UY 32296A UY 32296 A UY32296 A UY 32296A
Authority
UY
Uruguay
Prior art keywords
new compounds
agonists
preparation
pharmaceutically acceptable
general formula
Prior art date
Application number
UY0001032296A
Other languages
English (en)
Inventor
Giulio Matassa Victor
Aguilar Izquierdo Nuria
Mir Cepeda Marta
Carrascal Riera Marta
Fonquerna Pou Silvia
Cardus Figueras Aranzazu
Original Assignee
Almirall Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Almirall Sa filed Critical Almirall Sa
Publication of UY32296A publication Critical patent/UY32296A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A NUEVOS DERIVADOS DE FÓRMULA GENERAL (I), O SALES FARMACÉUTICAMENTE ACEPTABLES O N-ÓXIDOS DE LOS MISMOS, A SU MÉTODO DE PREPARACIÓN Y A SU USO COMO AGONISTAS DE LOS RECEPTORES DE 1-FOSFATO DE ESFINGOSINA (S1P1).
UY0001032296A 2008-12-26 2009-12-04 Nuevos compuestos UY32296A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08382090A EP2202232A1 (en) 2008-12-26 2008-12-26 1,2,4-oxadiazole derivatives and their therapeutic use

Publications (1)

Publication Number Publication Date
UY32296A true UY32296A (es) 2010-05-31

Family

ID=40671021

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001032296A UY32296A (es) 2008-12-26 2009-12-04 Nuevos compuestos

Country Status (18)

Country Link
US (1) US20110311485A1 (es)
EP (2) EP2202232A1 (es)
JP (1) JP2012513958A (es)
KR (1) KR20110104075A (es)
CN (1) CN102264731A (es)
AR (1) AR074902A1 (es)
AU (1) AU2009331959A1 (es)
BR (1) BRPI0918194A2 (es)
CA (1) CA2748397A1 (es)
CO (1) CO6341631A2 (es)
EA (1) EA201100975A1 (es)
EC (1) ECSP11011083A (es)
IL (1) IL213168A0 (es)
MX (1) MX2011006505A (es)
SG (1) SG172152A1 (es)
TW (1) TW201024287A (es)
UY (1) UY32296A (es)
WO (1) WO2010072352A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399451B2 (en) 2009-08-07 2013-03-19 Bristol-Myers Squibb Company Heterocyclic compounds
EP2366702A1 (en) * 2010-03-18 2011-09-21 Almirall, S.A. New oxadiazole derivatives
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
AU2011252223A1 (en) 2010-05-08 2012-12-06 Bayer Intellectual Property Gmbh Substituted heterocyclyl benzyl pyrazoles, and use thereof
CA2798374A1 (en) 2010-05-08 2011-11-17 Bayer Intellectual Property Gmbh Hydroxyalkyl benzyl pyrazoles, and use thereof for the treatment of hyperproliferative and angiogenic diseases
WO2012012477A1 (en) * 2010-07-20 2012-01-26 Bristol-Myers Squibb Company Substituted 3-phenyl-1,2,4-oxadiazole compounds
CN103298807A (zh) * 2010-11-03 2013-09-11 百时美施贵宝公司 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物
EP2455081A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of crohn's disease
EP2455080A1 (en) * 2010-11-23 2012-05-23 Almirall, S.A. S1P1 receptor agonists for use in the treatment of multiple sclerosis
KR101299512B1 (ko) * 2011-04-19 2013-08-22 전북대학교산학협력단 스핑고신 1-포스페이트를 유효성분으로 함유하는 관절염 질환 치료 조성물
WO2013025984A2 (en) * 2011-08-18 2013-02-21 Temple University Cannabinoid receptor treatments
ES2575604T3 (es) * 2012-01-13 2016-06-29 Bristol-Myers Squibb Company Compuestos de piridilo sustituidos con tiazolilo o tiadiazolilo útiles como inhibidores cinasa
UA114915C2 (uk) 2012-07-02 2017-08-28 Монсанто Текнолоджи Ллс Спосіб одержання 3,5-дизаміщених 1,2,4-оксадіазолів (варіанти)
KR101939657B1 (ko) 2013-02-20 2019-01-17 주식회사 엘지화학 스핑고신-1-인산 수용체 효능제, 그의 제조방법 및 그를 활성성분으로서 함유하는 약제학적 조성물
TWI613182B (zh) 2013-02-21 2018-02-01 必治妥美雅史谷比公司 雙環化合物
TW201534586A (zh) 2013-06-11 2015-09-16 Orion Corp 新穎ｃｙｐ１７抑制劑／抗雄激素劑
MA40082B1 (fr) 2014-08-20 2019-09-30 Bristol Myers Squibb Co Nouveau compose de substitution sphingosine phosphate utile traitement maladie rhumatisme
MA41139A (fr) 2014-12-11 2017-10-17 Actelion Pharmaceuticals Ltd Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1
CN114874209A (zh) * 2017-03-07 2022-08-09 豪夫迈·罗氏有限公司 噁二唑瞬时受体电位通道抑制剂
US11439623B2 (en) 2017-04-04 2022-09-13 Case Western Reserve University Method of modulating ribonucleotide reductase
CN108546266B (zh) * 2018-07-25 2020-09-22 上海毕得医药科技有限公司 一种1,4,6,7-四氢吡喃[4,3-c]吡唑-3-羧酸的合成方法
CN115087655A (zh) 2019-12-20 2022-09-20 辉瑞公司 苯并咪唑衍生物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2303792A (en) 1992-06-23 1994-01-24 Motorola, Inc. Multi-modulation scheme compatible radio
NZ502870A (en) 1995-06-21 2001-06-29 Asta Medica Ag Inhaler for powdered medicaments comprising a visual display device to indicate the discharge status of the inhaler
EP1383749B1 (de) * 2001-04-19 2005-11-02 Bayer HealthCare AG Arylsulfonamide als antivirale mittel
DE10129703A1 (de) 2001-06-22 2003-01-02 Sofotec Gmbh & Co Kg Zerstäubungssystem für eine Pulvermischung und Verfahren für Trockenpulverinhalatoren
DE10202940A1 (de) 2002-01-24 2003-07-31 Sofotec Gmbh & Co Kg Patrone für einen Pulverinhalator
DE60324416D1 (de) 2002-05-16 2008-12-11 Novartis Ag Verwendung von edg rezeptor bindenden wirkstoffen für die krebstherapie
GB0217152D0 (en) 2002-07-24 2002-09-04 Novartis Ag Organic compounds
EP1484057A1 (en) 2003-06-06 2004-12-08 Aventis Pharma Deutschland GmbH Use of 2-amino-1-3-propanediol derivatives for the manufacture of a medicament for the treatment of various types of pain
WO2005025553A2 (en) 2003-09-12 2005-03-24 Neuronova Ab Treatment of disorders of nervous systemsystem with fty720
GB0329498D0 (en) 2003-12-19 2004-01-28 Novartis Ag Organic compounds
CN101378741A (zh) 2006-01-27 2009-03-04 弗吉尼亚大学专利基金会 治疗神经性疼痛的方法
TWI389683B (zh) 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
CA2648303C (en) * 2006-04-03 2014-07-15 Astellas Pharma Inc. 5-[monocyclic(hetero)arylsubstituted-1,2,4-oxadliazol-3-yl]-(fused heteroaryl substituted) compounds and their use as s1p1 agonists
US8318812B2 (en) 2006-06-02 2012-11-27 The Ohio State University Research Foundation Therapeutic agents for the treatment of lymphoid malignancies
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP2392320A1 (en) 2006-08-17 2011-12-07 University Of Chicago Treatment of inflammatory diseases
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles

Also Published As

Publication number Publication date
ECSP11011083A (es) 2011-06-30
US20110311485A1 (en) 2011-12-22
JP2012513958A (ja) 2012-06-21
TW201024287A (en) 2010-07-01
CN102264731A (zh) 2011-11-30
MX2011006505A (es) 2011-07-12
AU2009331959A1 (en) 2011-06-30
WO2010072352A1 (en) 2010-07-01
AR074902A1 (es) 2011-02-23
CO6341631A2 (es) 2011-11-21
SG172152A1 (en) 2011-07-28
EA201100975A1 (ru) 2012-02-28
IL213168A0 (en) 2011-07-31
BRPI0918194A2 (pt) 2015-12-01
CA2748397A1 (en) 2010-07-01
EP2202232A1 (en) 2010-06-30
EP2370431A1 (en) 2011-10-05
KR20110104075A (ko) 2011-09-21

Similar Documents

Publication Publication Date Title
UY32296A (es) Nuevos compuestos
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
UY32292A (es) Agonistas de s1p1 y métodos de preparación y uso
UY31127A1 (es) Ligandos de oxiadazol del receptor metabotropico para el glutamato y su utilizacion como potenciadores - 841
UY33317A (es) Nuevos derivados de pirazol
CO6321282A2 (es) Derivados de piperidinilindol como inhibidores de aldosterona sintasa
CY1117147T1 (el) Παραγωγα [1,2,3]τριαζολο[4,5-d]πυριμιδiνης ως αγωνιστες του κaνναβινοειδους υποδοχεα 2
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
DOP2010000047A (es) Compuestos de pirazol y su uso como inhibidores de raf
EA201100612A1 (ru) Новые производные 2-амидотиадиазола
NI201002091A (es) Derivados de isoxazol y su uso como potenciadores de los receptores metabotrópicos de glutamato.
CO6351724A2 (es) Inhibidores de cmet
SV2011003894A (es) Nuevos compuestos halosustituidos
CU20100159A7 (es) Compuestos
UY32611A (es) Compuestos de 1-cianoetilheterociclilcarboxamida sustituidos 750
UY33075A (es) Derivados de ciclohexano y usos de los mismos
ECSP11011206A (es) Nuevos herbicidas.
NI200900183A (es) Compuestos de pirido [2,3-d] pirimidina - 7 - ona como inhibidores de pi3k - alfa para el tratamiento del cáncer.
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
ECSP11011133A (es) Nuevos herbicidas.
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
UY32055A (es) Derivados sustituidos de la 5-Halo-N2-[sustituido](1-metil-1H-imidazol-4-il)pirimidin-2,-diamina y sus sales farmacéuticamente aceptables, procesos de preparación, composiciones y aplicaciones.
CO6470820A2 (es) Espiro-epóxidos como productos intermedios
ECSP13013016A (es) Derivados de 2-amino-3-(imidazol-2-il)-piridin-4-ona, y su uso como inhibidores de la cinasa del receptor vegf
CU20110108A7 (es) [4-(1-amino-etil)-ciclohexil]-metil-aminas como antibacterianos

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20181219